Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07098806 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases

Study acronym: CA2024-LM-001
StatusRecruiting
PhasePhase 1/2
SponsorCerenome
Started2025-07-02
View on ClinicalTrials.gov ↗

Amendment history

2026-09-03
Study Status, Study Design v1
Phase changed: Phase 1 → Phase 1/2
Sponsor changed: Plus Therapeutics → Cerenome-9 characters
WasPlus Therapeutics
NowCerenome
2025-07-29
Original filing
Cerenome
5 trials monitored
See 1 trial at risk
This is an open-label, multicenter, Phase 1 study to determine the safety and efficacy of multiple doses at defined intervals of rhenium (186Re) obisbemeda (rhenium-186 nanoliposome, 186RNL) administered via intraventricular catheter for any primary solid tumor cancer with leptomeningeal metastases to identify an MTD/MFD for a given dose, interval duration, and number of doses.
Trial Details
NCT Number NCT07098806
Lead Sponsor Cerenome
Conditions Leptomeningeal Metastasis
Enrollment 24 participants
Start Date 2025-07-02
Primary Completion 2026-10-02 (estimated)
Study Completion 2031-10-02 (estimated)
Updated on ClinicalTrials.gov 2026-09-09